News

Fralin Biomedical Research Institute officially opens $90 million addition

State and local officials gathered for the grand opening of the newest building at the Fralin Biomedical Research Institute in Roanoke.

The COVID-19 pandemic delayed the ribbon-cutting ceremony for the 139,000-square-foot addition, which opened to researchers and staff last summer. The building, located at 4 Riverside Circle on the Virginia Tech Carilion Health Sciences campus, will accommodate at least 400 more researchers, students and staff.

“Today was worth the wait,” Carilion CEO Nancy Agee said. “We’re putting Roanoke on the map for biosciences.”

The $90-million building houses advanced MRI and CT imaging machines, 3D printers, and microscopes that can see down to the nanometer. One researcher said the microscope he uses for his research costs as much as two Lamborghinis — about $750,000.

Researchers are using this technology to study brain formation, cancer cells, heart disease and memory.

The facility is also home to Virginia Tech’s molecular diagnostics lab, which has processed more than 160,000 COVID-19 tests since April 2020. The facility also holds the Virginia Tech Animal Cancer Care and Research Center to provide medical, surgical and radiation oncology treatments to cats and dogs.

Rachana Somaiya, a graduate student at the institute, said she has been studying how circuits in the brain form and how that could connect to solutions for brain-centered diseases. She said her parents, who live in India, never got the opportunity to attend college and she is grateful to be able to study at the institute and in its newest facility.

“I feel thankful to be a scientist studying the stunning complexity of the brain,” Somaiya said.

“It’s because this institute gave me a chance for quality education and more importantly, a welcoming environment to conduct extraordinary scientific research.”

Learn more here.

Recent News

03/24/2026

Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform

Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros uniquesingle-molecule-counting platform and reinforcing its potential to improve

03/24/2026

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing